"Individual" bioequivalence studies not justified for all generics, Perrigo maintains.
This article was originally published in The Tan Sheet
Executive Summary
"INDIVIDUAL" BIOEQUIVALENCE STUDIES NOT JUSTIFIED FOR ALL GENERICS, PERRIGO maintains in March 2 comments submitted in response to FDA's recent draft guidance, "In Vivo Bioequivalence Studies based on Population and Individual Approaches." Perrigo "strongly disagrees with the case of individual bioequivalence results for all generic studies," the comments state. The company suggests "wholesale" use of the individual approach would increase the cost of studies "with no corresponding improvement to healthcare [of] the American public."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning